

Refine Search

Search Results -

Terms	Documents
L14 and angiogenesis	21

Database: US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

Search History

DATE: Friday, July 07, 2006 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L17</u>	L14 and angiogenesis	21	<u>L17</u>
<u>L16</u>	L15 and @py>1970<=2003	51	<u>L16</u>
<u>L15</u>	L14 and zinc	97	<u>L15</u>
<u>L14</u>	thiomolybdate	382	<u>L14</u>
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<u>L13</u>	6703050.pn.	1	<u>L13</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L12</u>	tetrapropylammonium adj tetrathiomolybdate	3	<u>L12</u>
<u>L11</u>	tetrabutylammonium adj tetrathiomolybdate	1	<u>L11</u>
<u>L10</u>	tetraethylammonium adj tetrathiomolybdate	3	<u>L10</u>
<u>L9</u>	tetramethylammonium adj tetrathiomolybdate	1	<u>L9</u>
<u>L8</u>	tetramethylammonium tetrathiomolybdate	23243	<u>L8</u>
<u>L7</u>	alkylammonium adj tetrathiomolybdate	1	<u>L7</u>
<u>L6</u>	alkylammonium tetrathiomolybdate	10567	<u>L6</u>

<u>L5</u>	alkylammonium adj thiomolybdate	1	<u>L5</u>
<u>L4</u>	L2 and zinc	1	<u>L4</u>
<i>DB=PGPB; PLUR=YES; OP=OR</i>			
<u>L3</u>	US-20040259945-A1.did.	1	<u>L3</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L2</u>	tetrapropylammonium adj tetrathiomolybdate	3	<u>L2</u>
<u>L1</u>	tetrapropylammonium adj tetrathiomolbdate	0	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L2 and zinc	1

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

Search History

DATE: Friday, July 07, 2006 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
<u>L4</u> L2 and zinc		1	<u>L4</u>
DB=PGPB; PLUR=YES; OP=OR			
<u>L3</u> US-20040259945-A1.did.		1	<u>L3</u>
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
<u>L2</u> tetrapropylammonium adj tetrathiomolybdate		3	<u>L2</u>
<u>L1</u> tetrapropylammonium adj tetrathiomolbdate		0	<u>L1</u>


END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
tetrapropylammonium adj tetrathiomolybdate	3

Database: US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:  

Search History

DATE: Friday, July 07, 2006 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> <u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<u>L12</u> tetrapropylammonium adj tetrathiomolybdate	3	<u>L12</u>
<u>L11</u> tetrabutylammonium adj tetrathiomolybdate	1	<u>L11</u>
<u>L10</u> tetraethylammonium adj tetrathiomolybdate	3	<u>L10</u>
<u>L9</u> tetramethylammonium adj tetrathiomolybdate	1	<u>L9</u>
<u>L8</u> tetramethylammonium tetrathiomolybdate	23243	<u>L8</u>
<u>L7</u> alkylammonium adj tetrathiomolybdate	1	<u>L7</u>
<u>L6</u> alkylammonium tetrathiomolybdate	10567	<u>L6</u>
<u>L5</u> alkylammonium adj thiomolybdate	1	<u>L5</u>
<u>L4</u> L2 and zinc	1	<u>L4</u>
<i>DB=PGPB; PLUR=YES; OP=OR</i>		
<u>L3</u> US-20040259945-A1.did.	1	<u>L3</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<u>L2</u> tetrapropylammonium adj tetrathiomolybdate	3	<u>L2</u>
<u>L1</u> tetrapropylammonium adj tetrathiomolybdate	0	<u>L1</u>

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptau125zxf

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 07 Coverage of Research Disclosure reinstated in DWPI

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Due to scheduled maintenance of STN on Sunday, July 9, 2006,
some databases may not be available until 04:00 (4:00 AM)
Eastern Daylight Time.

FILE 'HOME' ENTERED AT 16:11:28 ON 07 JUL 2006

=> file ca,medline,biosis,uspatfull,drugu,wpids,caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'CA' ENTERED AT 16:12:33 ON 07 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:12:33 ON 07 JUL 2006

FILE 'BIOSIS' ENTERED AT 16:12:33 ON 07 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 16:12:33 ON 07 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DRUGU' ENTERED AT 16:12:33 ON 07 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPIDS' ENTERED AT 16:12:33 ON 07 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CAPLUS' ENTERED AT 16:12:33 ON 07 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s tetraalkylammonium (w) tetrathiomolybdate
L1 8 TETRAALKYLAMMONIUM (W) TETRATHIOMOLYBDATE

=> remove dup 11
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the system.

To delete a saved query, saved answer set, saved L-number list, SDI request, batch request, mailing list, or user-defined cluster, format, or search field, enter the name. The name may include ? for left, right, or simultaneous left and right truncation.

Examples:

DELETE BIO?/Q	- delete query names starting with BIO
DELETE ?DRUG/A	- delete answer set names ending with DRUG
DELETE ?ELEC?/L	- delete L-number lists containing ELEC
DELETE ANTICOAG/S	- delete SDI request
DELETE ENZYME/B	- delete batch request
DELETE .MYCLUSTER	- delete user-defined cluster
DELETE .MYFORMAT	- delete user-defined display format
DELETE .MYFIELD	- delete user-defined search field
DELETE NAMELIST MYLIST	- delete mailing list

To delete an ordered document or an offline print, enter its number.

Examples:

DELETE P123001C	- delete print request
DELETE D134002C	- delete document order request

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

DELETE L21	- delete a single L-number
DELETE L3-L6	- delete a range of L-numbers
DELETE LAST 4	- delete the last 4 L-numbers
DELETE L33-	- delete L33 and any higher L-number
DELETE -L55	- delete L55 and any lower L-number
DELETE L2-L6 RENUMBER	- delete a range of L-numbers and renumber remaining L-numbers
DELETE RENUMBER	- renumber L-numbers after deletion of intermediate L-numbers

Entire sets of saved items, SDI requests, batch requests, user-defined items, or E-numbers can be deleted.

Examples:

DELETE SAVED/Q	- delete all saved queries
DELETE SAVED/A	- delete all saved answer sets
DELETE SAVED/L	- delete all saved L-number lists
DELETE SAVED	- delete all saved queries, answer sets, and L-number lists
DELETE SAVED/S	- delete all SDI requests
DELETE SAVED/B	- delete all batch requests
DELETE CLUSTER	- delete all user-defined clusters
DELETE FORMAT	- delete all user-defined display formats
DELETE FIELD	- delete all user-defined search fields
DELETE SELECT	- delete all E-numbers
DELETE HISTORY	- delete all L-numbers and restart the session at L1

To delete an entire multifile SDI request, enter DELETE and the name of the request. To delete a component from the multifile SDI, enter DELETE and the name of the component.

=> d 11 1-8 bib, ab

L1 ANSWER 1 OF 8 CA COPYRIGHT 2006 ACS on STN
AN 140:139472 CA
TI Tetrapropylammonium tetrathiomolybdate and related compounds for
anti-angiogenic therapies
IN Brewer, George J.; Merajver, Sofia D.; Coucouvanis, Dimitri
PA The University of Michigan, USA; Univ Michigan
SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009072	A2	20040129	WO 2003-US22914	20030723
	WO 2004009072	A3	20040408		
	WO 2004009072	B1	20040708		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

CA 2493341	AA 20040129	CA 2003-2493341	20030723
AU 2003261222	A1 20040209	AU 2003-261222	20030723
US 2004259945	A1 20041223	US 2003-625839	20030723
BR 2003012845	A 20050607	BR 2003-12845	20030723
EP 1539131	A2 20050615	EP 2003-765921	20030723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1688303	A 20051026	CN 2003-820746	20030723
JP 2005538093	T2 20051215	JP 2004-523295	20030723
ZA 2005001162	A 20050905	ZA 2005-1162	20050209
NO 2005000902	A 20050419	NO 2005-902	20050218
PRAI US 2002-397804P	P 20020723		
	WO 2003-US22914	W 20030723	

AB Disclosed are copper-binding compds. with improved properties and methods of using such compds. in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compds., which is achieved without reduction in efficacy. Pharmaceutical compns., therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 2 OF 8 CA COPYRIGHT 2006 ACS on STN

AN 136:209573 CA

TI Synthesis of tetraalkylammonium thiometallates in aqueous solution

AU Alonso, G.; Yang, J.; Siadati, M. H.; Chianelli, R. R.

CS Centro de Investigacion en Materiales Avanzados, Departamento de Catalisis, Chihuahua, Mexico City, Mex.

SO Inorganica Chimica Acta (2001), 325(1,2), 193-197
CODEN: ICHAA3; ISSN: 0020-1693

PB Elsevier Science S.A.

DT Journal

LA English

AB An aqueous solution method for the preparation of tetraalkylammonium thiometallates

(R4N)2MS4 (R = pentyl or hexyl and, M = Mo or W) is reported. The one-step rapid substitution of [NH4]+ ions from ammonium thiomolybdate (ATM) and ammonium thiotungstate (ATT) with [(pentyl)4N]+ and [(hexyl)4N]+ ions during reactions with (pentyl)4NBr and (hexyl)4NBr, resp., is described. One application for these tetraalkylammonium thiomolybdates and thiotungstates is as precursors for MoS2 and WS2 catalysts, which were used in industrial hydrodesulfurization and hydrodenitrogenation processes. The synthesized thiometallates were characterized using the spectroscopic techniques FTIR, UV and, NMR (13C NMR) for determining their chemical

structures. Thermal analyses (TGA-DTA) were done to study the fragmentation and decomposition behavior of their mol. structures.

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 8 CA COPYRIGHT 2006 ACS on STN

AN 125:86999 CA

TI A new approach to some 1,6-dideoxy-1,6-epithio sugars

AU Driguez, Hugues; McAuliffe, C.; Stick, Robert V.; Tilbrook, D. Matthew G.; Williams, Spencer J.

CS Centre Recherches Macromolecules Vegetales, CERMAV-CNRS, Grenoble, 38041, Fr.

SO Australian Journal of Chemistry (1996), 49(3), 343-348

CODEN: AJCHAS; ISSN: 0004-9425

PB Commonwealth Scientific and Industrial Research Organization

DT Journal

LA English

OS CASREACT 125:86999

AB The treatment of hexopyranosyl bromides, also activated at C 6 (Br, OTs, OMs), with H2S/HCONMe2 under basic conditions gives 1,6-dideoxy-1,6-epithio sugars, e.g. I (R = N3, X = S). An analogous treatment of one

doubly activated hexopyranosyl bromide with sodium hydrogen selenide has led to a novel 1,6-dideoxy-1,6-episeleno sugars, e.g. I (R = OAc, X = Se), which displayed interesting NMR spectra. Finally, in an attempt to prepare 1,6-dideoxy 1,6-epidithio sugars, a tetraalkylammonium tetrathiomolybdate reagent was found to be the reagent of choice for converting doubly activated hexopyranosyl bromides into 1,6-dideoxy-1,6-epithio sugars.

L1 ANSWER 4 OF 8 USPATFULL on STN
AN 2004:328120 USPATFULL
TI Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
IN Brewer, George J., Ann Arbor, MI, UNITED STATES
Merajver, Sofia D., Ann Arbor, MI, UNITED STATES
Coucouvanis, Dimitri, Ann Arbor, MI, UNITED STATES
PA The Regents of The University of Michigan (U.S. corporation)
PI US 2004259945 A1 20041223
AI US 2003-625839 A1 20030723 (10)
PRAI US 2002-397804P 20020723 (60)
DT Utility
FS APPLICATION
LREP shelley p m fussey, williams morgan & amerson, 10333 richmond, suite 1100, houston, TX, 77042
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are copper-binding compounds with improved properties and methods of using such compounds in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compounds, which is achieved without reduction in efficacy. Pharmaceutical compositions, therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 5 OF 8 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-203433 [19] WPIDS
DNC C2004-080111
TI Composition, useful to treat/prevent disease associated with aberrant vascularization e.g. wet type macular degeneration, rheumatoid arthritis and cancer, comprises a tetraalkylammonium tetrathiomolybdate compound.
DC B05
IN BREWER, G J; COUCOUVANIS, D; MERAJVER, S D; MERAJVER, S
PA (UNMI) UNIV MICHIGAN
CYC 106
PI WO 2004009072 A2 20040129 (200419)* EN 140
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH
PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN
YU ZA ZM ZW
AU 2003261222 A1 20040209 (200450)
US 2004259945 A1 20041223 (200504)
BR 2003012845 A 20050607 (200538)
EP 1539131 A2 20050615 (200539) EN
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
MC MK NL PT RO SE SI SK TR
NO 2005000902 A 20050419 (200540)
KR 2005025976 A 20050314 (200574)
JP 2005538093 W 20051215 (200582)
CN 1688303 A 20051026 (200618)

MX 2005000875 A1 20051001 (200620)
 ZA 2005001162 A 20051130 (200628) 138
 ADT WO 2004009072 A2 WO 2003-US22914 20030723; AU 2003261222 A1 AU 2003-261222
 20030723; US 2004259945 A1 Provisional US 2002-397804P 20020723, US
 2003-625839 20030723; BR 2003012845 A BR 2003-12845 20030723, WO
 2003-US22914 20030723; EP 1539131 A2 EP 2003-765921 20030723, WO
 2003-US22914 20030723; NO 2005000902 A WO 2003-US22914 20030723, NO
 2005-902 20050218; KR 2005025976 A KR 2005-701226 20050122; JP 2005538093
 W WO 2003-US22914 20030723, JP 2004-523295 20030723; CN 1688303 A CN
 2003-820746 20030723; MX 2005000875 A1 WO 2003-US22914 20030723, MX
 2005-875 20050121; ZA 2005001162 A ZA 2005-1162 20050209

FDT AU 2003261222 A1 Based on WO 2004009072; BR 2003012845 A Based on WO
 2004009072; EP 1539131 A2 Based on WO 2004009072; JP 2005538093 W Based on
 WO 2004009072; MX 2005000875 A1 Based on WO 2004009072

PRAI US 2002-397804P 20020723; US 2003-625839 20030723

AB WO2004009072 A UPAB: 20040318

NOVELTY - Composition (A) comprises at least one tetraalkylammonium tetrathiomolybdate compound (I) and a pharmaceutically acceptable excipient.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a kit comprising, in at least one container, at least one compound (I) and either a second, distinct therapeutic agent (II) or a component of an assay system for determining serum ceruloplasmin levels (III).

ACTIVITY - Ophthalmological; Cytostatic; Antirheumatic; Antiarthritic, Antiangiogenic.

MECHANISM OF ACTION - None given in the source material.

USE - (A) is used for treatment/prevention of a disease associated with aberrant vascularization (preferably wet type macular degeneration, rheumatoid arthritis or cancer) in an animal (preferably a human) that has or is at risk for developing the disease (claimed).

ADVANTAGE - (I) displays increased stability and shelf life, without significant loss of solubility or therapeutic efficacy. This allows the drug to be handled pharmaceutically in bulk without exquisite attention to air exclusion. The stability of (I) was studied under conditions that exacerbate instability (i.e. by leaving the drug in open Petri dishes at room temperature) using a tetrathiomolybdate preparation as control. The half life of tetrapropylammonium tetrathiomolybdate under these conditions was determined to be about 180 days whereas it was about 40 days for the control.

Dwg. 0/5

L1 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:80492 CAPLUS

DN 140:139472

TI Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies

IN Brewer, George J.; Merajver, Sofia D.; Coucouvanis, Dimitri
 PA The University of Michigan, USA; Univ Michigan

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009072	A2	20040129	WO 2003-US22914	20030723
	WO 2004009072	A3	20040408		
	WO 2004009072	B1	20040708		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2493341 AA 20040129 CA 2003-2493341 20030723
 AU 2003261222 A1 20040209 AU 2003-261222 20030723
 US 2004259945 A1 20041223 US 2003-625839 20030723
 BR 2003012845 A 20050607 BR 2003-12845 20030723
 EP 1539131 A2 20050615 EP 2003-765921 20030723
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 CN 1688303 A 20051026 CN 2003-820746 20030723
 JP 2005538093 T2 20051215 JP 2004-523295 20030723
 ZA 2005001162 A 20050905 ZA 2005-1162 20050209
 NO 2005000902 A 20050419 NO 2005-902 20050218
 PRAI US 2002-397804P P 20020723
 WO 2003-US22914 W 20030723

AB Disclosed are copper-binding compds. with improved properties and methods of using such compds. in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compds., which is achieved without reduction in efficacy. Pharmaceutical compns., therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:855323 CAPLUS
 DN 136:209573
 TI Synthesis of tetraalkylammonium thiometallates in aqueous solution
 AU Alonso, G.; Yang, J.; Siadati, M. H.; Chianelli, R. R.
 CS Centro de Investigacion en Materiales Avanzados, Departamento de Catalisis, Chihuahua, Mexico City, Mex.
 SO Inorganica Chimica Acta (2001), 325(1,2), 193-197
 CODEN: ICHAA3; ISSN: 0020-1693
 PB Elsevier Science S.A.
 DT Journal
 LA English
 AB An aqueous solution method for the preparation of tetraalkylammonium thiometallates
 (R4N)2MS4 (R = pentyl or hexyl and, M = Mo or W) is reported. The one-step rapid substitution of [NH4]+ ions from ammonium thiomolybdate (ATM) and ammonium thiotungstate (ATT) with [(pentyl)4N]+ and [(hexyl)4N]+ ions during reactions with (pentyl)4NBr and (hexyl)4NBr, resp., is described. One application for these tetraalkylammonium thiomolybdates and thiotungstates is as precursors for MoS2 and WS2 catalysts, which were used in industrial hydrodesulfurization and hydrodenitrogenation processes. The synthesized thiometallates were characterized using the spectroscopic techniques FTIR, UV and, NMR (13C NMR) for determining their chemical structures. Thermal analyses (TGA-DTA) were done to study the fragmentation and decomposition behavior of their mol. structures.
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:319437 CAPLUS
 DN 125:86999
 TI A new approach to some 1,6-dideoxy-1,6-epithio sugars
 AU Driguez, Hugues; McAuliffe, C.; Stick, Robert V.; Tilbrook, D. Matthew G.; Williams, Spencer J.
 CS Centre Recherches Macromolecules Vegetales, CERMAV-CNRS, Grenoble, 38041, Fr.
 SO Australian Journal of Chemistry (1996), 49(3), 343-348
 CODEN: AJCHAS; ISSN: 0004-9425
 PB Commonwealth Scientific and Industrial Research Organization

DT Journal

LA English

OS CASREACT 125:86999

AB The treatment of hexopyranosyl bromides, also activated at C 6 (Br, OTs, OMs), with H₂S/HCONMe₂ under basic conditions gives 1,6-dideoxy-1,6-epithio sugars, e.g. I (R = N₃, X = S). An analogous treatment of one doubly activated hexopyranosyl bromide with sodium hydrogen selenide has led to a novel 1,6-dideoxy-1,6-episeleno sugars, e.g. I (R = OAc, X = Se), which displayed interesting NMR spectra. Finally, in an attempt to prepare 1,6-dideoxy 1,6-epidithio sugars, a tetraalkylammonium tetrathiomolybdate reagent was found to be the reagent of choice for converting doubly activated hexopyranosyl bromides into 1,6-dideoxy-1,6-epithio sugars.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptau125zxf

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Due to scheduled maintenance of STN on Sunday, July 9, 2006, some databases may not be available until 04:00 (4:00 AM) Eastern Daylight Time.

FILE 'HOME' ENTERED AT 16:48:20 ON 07 JUL 2006

=> file ca, caplus, medline, biosis, druqu, uspatfull, wpinds

'WPINDS' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files

that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE) :wpids

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.63	0.63

FULL ESTIMATED COST

FILE 'CA' ENTERED AT 16:50:09 ON 07 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 16:50:09 ON 07 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:50:09 ON 07 JUL 2006

FILE 'BIOSIS' ENTERED AT 16:50:09 ON 07 JUL 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'DRUGU' ENTERED AT 16:50:09 ON 07 JUL 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 16:50:09 ON 07 JUL 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:50:09 ON 07 JUL 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s tetrapropylammonium (w) tetrathiomolybdate

L1 14 TETRAPROPYLAAMMONIUM (W) TETRATHIOMOLYBDATE

=> d 11 1-14 bib, ab

L1 ANSWER 1 OF 14 CA COPYRIGHT 2006 ACS on STN

AN 142:205454 CA

TI Preparation of amorphous sulfide sieves

IN Siadati, Mohammad H.; Alonso, Gabriel; Chianelli, Russell R.

PA Centro De Investigacion En Materiales Avanzados, S.C., USA

SO U.S. Pat. Appl. Publ., 46 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----	-----
PI	US 2005032636	A1	20050210	US 2004-819480	20040407
	WO 2005031025	A2	20050407	WO 2004-US10578	20040407
	WO 2005031025	A3	20060223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-460951P

P 20030407

AB The present invention involves methods and compns. for synthesizing catalysts/porous materials. In some embodiments, the resulting materials are amorphous sulfide sieves that can be mass-produced for a variety of uses. In some embodiments, methods of the invention concern any suitable precursor (such as thiomolybdate salt) that is exposed to a high pressure pre-compaction, if need be. For instance, in some cases the final bulk shape (but highly porous) may be same as the original bulk shape. The compacted/uncompacted precursor is then subjected to an open-flow hot isostatic pressing, which causes the precursor to decompose and convert to a highly porous material/catalyst.

L1 ANSWER 2 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 140:139472 CA
TI Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
IN Brewer, George J.; Merajver, Sofia D.; Coucouvanis, Dimitri
PA The University of Michigan, USA; Univ Michigan
SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009072	A2	20040129	WO 2003-US22914	20030723
	WO 2004009072	A3	20040408		
	WO 2004009072	B1	20040708		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2493341	AA	20040129	CA 2003-2493341	20030723
	AU 2003261222	A1	20040209	AU 2003-261222	20030723
	US 2004259945	A1	20041223	US 2003-625839	20030723
	BR 2003012845	A	20050607	BR 2003-12845	20030723
	EP 1539131	A2	20050615	EP 2003-765921	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1688303	A	20051026	CN 2003-820746	20030723
	JP 2005538093	T2	20051215	JP 2004-523295	20030723
	ZA 2005001162	A	20050905	ZA 2005-1162	20050209
	NO 2005000902	A	20050419	NO 2005-902	20050218
PRAI	US 2002-397804P	P	20020723		
	WO 2003-US22914	W	20030723		

AB Disclosed are copper-binding compds. with improved properties and methods of using such compds. in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compds., which is achieved without reduction in efficacy. Pharmaceutical compns., therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 3 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 139:236000 CA
TI Mesoporous carbon-containing MoS₂ materials formed from the in situ decomposition of tetraalkylammonium thiomolybdates
AU Alonso, Gabriel; Berhault, Gilles; Paraguay, Francisco; Rivera, Eric; Fuentes, Sergio; Chianelli, Russell R.
CS Centro de Investigacion en Materiales Avanzados, Chihuahua, 31109, Mex.

SO Materials Research Bulletin (2003), 38(6), 1045-1055
CODEN: MRBUAC; ISSN: 0025-5408
PB Elsevier Science Ltd.
DT Journal
LA English
AB Molybdenum disulfide with unique mesoporous structure was synthesized from tetraalkylammonium thiometallate precursors *in situ* decomposed in a batch reactor in the presence of dibenzothiophene (DBT). The precursors used in this study were tetraalkylammonium thiomolybdates with alkyl groups ranging from Pr to octyl. Molybdenum disulfide thus prepared presents high surface area (from 255 up to 329 m²/g), high content of carbon (C/Mo=2.7-4.0) and type IV nitrogen adsorption-desorption isotherms when decomposed from tetrahexyl-, tetraheptyl- or tetraoctylammonium thiomolybdates. The as-formed materials are poorly crystallized with a very weak intensity of the (0 0 2) peak of the 2H-MoS₂ structure. Such diffraction patterns are characteristic of exfoliated samples. Characterization by TEM shows a disordered layered structure with no long range order for the MoS₂ catalysts. Therefore, the nature of the alkyl group in the precursor affects both the surface area and the pore size distribution of the final MoS₂ catalysts with a progressive morphological modification up to a mesoporous organization.

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 135:146200 CA
TI Synthesis and characterization of tetraalkylammonium thiomolybdates and thiotungstates in aqueous solution
AU Alonso, G.; Berhault, G.; Chianelli, R. R.
CS Departamento de Catalisis, Centro de Investigacion en Materiales Avanzados, Chihuahua, 31109, Mex.
SO Inorganica Chimica Acta (2001), 316(1,2), 105-109
CODEN: ICHAA3; ISSN: 0020-1693
PB Elsevier Science S.A.
DT Journal
LA English
OS CASREACT 135:146200
AB In this work is reported a method for the preparation of (R₄N)₂MS₄ (R = Pr, Oct and M = Mo, W) in aqueous solution. The rapid substitution of (NH₄)₂ salts with [(Pro)₄N]₂ and [(Oct)₄N]₂ via reaction with (Pro)₄NBr and (Oct)₄NBr is described. Characterization of the thiomolybdates and thiotungstates was performed using FTIR, UV-visible spectroscopies and TGA (TG-DTA).

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 117:263533 CA
TI Molecular architecture of copper(I) thiometallate complexes. Example of a cubane with an extra face, (NPr₄)₃[MS₄Cu₄Cl₅] (M = molybdenum, tungsten)
AU Jeannin, Yves; Secheresse, Francis; Bernes, Sylvain; Robert, Francis
CS Lab. Chim. Met. Transit., Univ. Pierre et Marie Curie, Paris, 75252, Fr.
SO Inorganica Chimica Acta (1992), 198-200, 493-505
CODEN: ICHAA3; ISSN: 0020-1693
DT Journal
LA English
AB The various structures obtained by addition of Cu(I) to MS₄2- (M = Mo, W) are described and illustrated by examples recently reported in the literature. The preparation and structural characterization of (NPr₄)₃[MS₄Cu₄Cl₅] are given together with the connections which exist between open and closed cubane structures.

L1 ANSWER 6 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 116:50301 CA
TI Heterobimetallic aggregates of copper(I) with thiotungstate and

-molybdate. Cation effect in aggregation of $MS_4Cu_4Cl_4$ units, a crystallographic study
AU Secheresse, Francis; Bernes, Sylvain; Robert, Francis; Jeannin, Yves
CS Lab. Chim. Metal Transition, Univ. Pierre et Marie Curie, Paris, 75252, Fr.
SO Journal of the Chemical Society, Dalton Transactions: Inorganic Chemistry (1972-1999) (1991), (11), 2875-81
CODEN: JCDTBI; ISSN: 0300-9246
DT Journal
LA English
AB Reaction of $[MS_4]^{2-}$ (M = Mo, W) with CuCl in CH_2Cl_2 or MeCN gives a new set of bimetallic compds. isolated with various geometries for the same 1:4:4 M:S:Cu composition. Crystals of $[NBu_4]_2[MoS_4Cu_4Cl_4]$ are tetragonal, space group I.hivin.4/m, Z = 2, R = 0.058, R' = 0.056. The crystal structure reveals discrete $[MoS_4Cu_4Cl_4]^{2-}$ separated in the lattice by $[NBu_4]^+$. The isostructural $[NBu_4]_2[M/S_4Cu_4Cl_4]$ (1b) was isolated and characterized: tetragonal, space group I.hivin.4/m, Z = 2. The structure of $[PPh_4][NPr_4][MoS_4Cu_4Cl_4]$ consists of a dimeric aggregate: monoclinic, space group P21/n, Z = 4, R = 0.056, R' = 0.062. $[NPr_4]_2[WS_4Cu_4Cl_4]$ is polymerized through linear chains. Crystals are triclinic, space group P.hivin.1, Z = 2, R = 0.031, R' = 0.030. The isostructural $[NPr_4]_2[MoS_4Cu_4Cl_4]$ (3a) was also characterized: triclinic, space group P.hivin.1, Z = 2. The arrangements of the mono-, di- and polymeric aggregates in the lattice are discussed in terms of the size of the counter anion. For 1b and 3a only the cell dimensions were determined

L1 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:123172 CAPLUS
DN 142:205454
TI Preparation of amorphous sulfide sieves
IN Siadati, Mohammad H.; Alonso, Gabriel; Chianelli, Russell R.
PA Centro De Investigacion En Materiales Avanzados, S.C., USA
SO U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005032636	A1	20050210	US 2004-819480	20040407
	WO 2005031025	A2	20050407	WO 2004-US10578	20040407
	WO 2005031025	A3	20060223		
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

PRAI US 2003-460951P P 20030407

AB The present invention involves methods and compns. for synthesizing catalysts/porous materials. In some embodiments, the resulting materials are amorphous sulfide sieves that can be mass-produced for a variety of uses. In some embodiments, methods of the invention concern any suitable precursor (such as thiomolybdate salt) that is exposed to a high pressure pre-compaction, if need be. For instance, in some cases the final bulk shape (but highly porous) may be same as the original bulk shape. The compacted/uncompacted precursor is then subjected to an open-flow hot isostatic pressing, which causes the precursor to decompose and convert to a highly porous material/catalyst.

L1 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:80492 CAPLUS
 DN 140:139472
 TI Tetrapropylammonium tetrathiomolybdate and related
 compounds for anti-angiogenic therapies
 IN Brewer, George J.; Merajver, Sofia D.; Coucouvanis, Dimitri
 PA The University of Michigan, USA; Univ Michigan
 SO PCT Int. Appl., 140 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009072	A2	20040129	WO 2003-US22914	20030723
	WO 2004009072	A3	20040408		
	WO 2004009072	B1	20040708		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2493341	AA	20040129	CA 2003-2493341	20030723
	AU 2003261222	A1	20040209	AU 2003-261222	20030723
	US 2004259945	A1	20041223	US 2003-625839	20030723
	BR 2003012845	A	20050607	BR 2003-12845	20030723
	EP 1539131	A2	20050615	EP 2003-765921	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1688303	A	20051026	CN 2003-820746	20030723
	JP 2005538093	T2	20051215	JP 2004-523295	20030723
	ZA 2005001162	A	20050905	ZA 2005-1162	20050209
	NO 2005000902	A	20050419	NO 2005-902	20050218
PRAI	US 2002-397804P	P	20020723		
	WO 2003-US22914	W	20030723		
AB	Disclosed are copper-binding compds. with improved properties and methods of using such compds. in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compds., which is achieved without reduction in efficacy. Pharmaceutical compns., therapeutic kits and combination treatment methods and uses are also provided.				

this study were tetraalkylammonium thiomolybdates with alkyl groups ranging from Pr to octyl. Molybdenum disulfide thus prepared presents high surface area (from 255 up to 329 m²/g), high content of carbon (C/Mo=2.7-4.0) and type IV nitrogen adsorption-desorption isotherms when decomposed from tetrahexyl-, tetraheptyl- or tetraoctylammonium thiomolybdates. The as-formed materials are poorly crystallized with a very weak intensity of the (0 0 2) peak of the 2H-MoS₂ structure. Such diffraction patterns are characteristic of exfoliated samples. Characterization by TEM shows a disordered layered structure with no long range order for the MoS₂ catalysts. Therefore, the nature of the alkyl group in the precursor affects both the surface area and the pore size distribution of the final MoS₂ catalysts with a progressive morphol. modification up to a mesoporous organization.

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:314844 CAPLUS
DN 135:146200
TI Synthesis and characterization of tetraalkylammonium thiomolybdates and thiotungstates in aqueous solution
AU Alonso, G.; Berhault, G.; Chianelli, R. R.
CS Departamento de Catalisis, Centro de Investigacion en Materiales Avanzados, Chihuahua, 31109, Mex.
SO Inorganica Chimica Acta (2001), 316(1,2), 105-109
CODEN: ICHAA3; ISSN: 0020-1693
PB Elsevier Science S.A.
DT Journal
LA English
OS CASREACT 135:146200
AB In this work is reported a method for the preparation of (R₄N)₂MS₄ (R = Pr, Oct and M = Mo, W) in aqueous solution. The rapid substitution of (NH₄)₂ salts with [(Pro)4N] and [(Oct)4N] via reaction with (Pro)4NBr and (Oct)4NBr is described. Characterization of the thiomolybdates and thiotungstates was performed using FTIR, UV-visible spectroscopies and TGA (TG-DTA).

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:663533 CAPLUS
DN 117:263533
TI Molecular architecture of copper(I) thiometallate complexes. Example of a cubane with an extra face, (NPr₄)₃[MS₄Cu₄Cl₅] (M = molybdenum, tungsten)
AU Jeannin, Yves; Secheresse, Francis; Bernes, Sylvain; Robert, Francis
CS Lab. Chim. Met. Transit., Univ. Pierre et Marie Curie, Paris, 75252, Fr.
SO Inorganica Chimica Acta (1992), 198-200, 493-505
CODEN: ICHAA3; ISSN: 0020-1693
DT Journal
LA English
AB The various structures obtained by addition of Cu(I) to MS₄2- (M = Mo, W) are described and illustrated by examples recently reported in the literature. The preparation and structural characterization of (NPr₄)₃[MS₄Cu₄Cl₅] are given together with the connections which exist between open and closed cubane structures.

L1 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:50301 CAPLUS
DN 116:50301
TI Heterobimetallic aggregates of copper(I) with thiotungstate and -molybdate. Cation effect in aggregation of MS₄Cu₄Cl₄ units, a crystallographic study
AU Secheresse, Francis; Bernes, Sylvain; Robert, Francis; Jeannin, Yves
CS Lab. Chim. Metaux Transition, Univ. Pierre et Marie Curie, Paris, 75252, Fr.

SO Journal of the Chemical Society, Dalton Transactions: Inorganic Chemistry (1972-1999) (1991), (11), 2875-81
CODEN: JCDTBI; ISSN: 0300-9246
DT Journal
LA English
AB Reaction of $[MS_4]^{2-}$ ($M = Mo, W$) with $CuCl$ in CH_2Cl_2 or $MeCN$ gives a new set of bimetallic compds. isolated with various geometries for the same 1:4:4 M:S:Cu composition. Crystals of $[NBu_4]_2[MoS_4Cu_4Cl_4]$ are tetragonal, space group I.hivin.4/m, $Z = 2$, $R = 0.058$, $R' = 0.056$. The crystal structure reveals discrete $[MoS_4Cu_4Cl_4]^{2-}$ separated in the lattice by $[NBu_4]^+$. The isostructural $[NBu_4]_2[M/S_4Cu_4Cl_4]$ (1b) was isolated and characterized: tetragonal, space group I.hivin.4/m, $Z = 2$. The structure of $[PPh_4][NPr_4][MoS_4Cu_4Cl_4]$ consists of a dimeric aggregate: monoclinic, space group P21/n, $Z = 4$, $R = 0.056$, $R' = 0.062$. $[NPr_4]_2[WS_4Cu_4Cl_4]$ is polymerized through linear chains. Crystals are triclinic, space group P.hivin.1, $Z = 2$, $R = 0.031$, $R' = 0.030$. The isostructural $[NPr_4]_2[MoS_4Cu_4Cl_4]$ (3a) was also characterized: triclinic, space group P.hivin.1, $Z = 2$. The arrangements of the mono-, di- and polymeric aggregates in the lattice are discussed in terms of the size of the counter anion. For 1b and 3a only the cell dimensions were determined

L1 ANSWER 13 OF 14 USPATFULL on STN
AN 2004:328120 USPATFULL
TI Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
IN Brewer, George J., Ann Arbor, MI, UNITED STATES
Merajver, Sofia D., Ann Arbor, MI, UNITED STATES
Coucouvanis, Dimitri, Ann Arbor, MI, UNITED STATES
PA The Regents of The University of Michigan (U.S. corporation)
PI US 2004259945 A1 20041223
AI US 2003-625839 A1 20030723 (10)
PRAI US 2002-397804P 20020723 (60)
DT Utility
FS APPLICATION
LREP shelley p m fussey, williams morgan & amerson, 10333 richmond, suite 1100, houston, TX, 77042
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5014

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are copper-binding compounds with improved properties and methods of using such compounds in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compounds, which is achieved without reduction in efficacy. Pharmaceutical compositions, therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 14 OF 14 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-203433 [19] WPIDS
DNC C2004-080111
TI Composition, useful to treat/prevent disease associated with aberrant vascularization e.g. wet type macular degeneration, rheumatoid arthritis and cancer, comprises a tetraalkylammonium tetrathiomolybdate compound.
DC B05
IN BREWER, G J; COUCOUVANIS, D; MERAJVER, S D; MERAJVER, S
PA (UNMI) UNIV MICHIGAN
CYC 106
PI WO 2004009072 A2 20040129 (200419)* EN 140
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH

PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN
 YU ZA ZM ZW
 AU 2003261222 A1 20040209 (200450)
 US 2004259945 A1 20041223 (200504)
 BR 2003012845 A 20050607 (200538)
 EP 1539131 A2 20050615 (200539) EN
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
 MC MK NL PT RO SE SI SK TR
 NO 2005000902 A 20050419 (200540)
 KR 2005025976 A 20050314 (200574)
 JP 2005538093 W 20051215 (200582) 97
 CN 1688303 A 20051026 (200618)
 MX 2005000875 A1 20051001 (200620)
 ZA 2005001162 A 20051130 (200628) 138
 ADT WO 2004009072 A2 WO 2003-US22914 20030723; AU 2003261222 A1 AU 2003-261222
 20030723; US 2004259945 A1 Provisional US 2002-397804P 20020723, US
 2003-625839 20030723; BR 2003012845 A BR 2003-12845 20030723, WO
 2003-US22914 20030723; EP 1539131 A2 EP 2003-765921 20030723, WO
 2003-US22914 20030723; NO 2005000902 A WO 2003-US22914 20030723, NO
 2005-902 20050218; KR 2005025976 A KR 2005-701226 20050122; JP 2005538093
 W WO 2003-US22914 20030723, JP 2004-523295 20030723; CN 1688303 A CN
 2003-820746 20030723; MX 2005000875 A1 WO 2003-US22914 20030723, MX
 2005-875 20050121; ZA 2005001162 A ZA 2005-1162 20050209
 FDT AU 2003261222 A1 Based on WO 2004009072; BR 2003012845 A Based on WO
 2004009072; EP 1539131 A2 Based on WO 2004009072; JP 2005538093 W Based on
 WO 2004009072; MX 2005000875 A1 Based on WO 2004009072
 PRAI US 2002-397804P 20020723; US 2003-625839 20030723
 AB WO2004009072 A UPAB: 20040318
 NOVELTY - Composition (A) comprises at least one tetraalkylammonium
 tetrathiomolybdate compound (I) and a pharmaceutically acceptable
 excipient.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a
 kit comprising, in at least one container, at least one compound (I) and
 either a second, distinct therapeutic agent (II) or a component of an
 assay system for determining serum ceruloplasmin levels (III).

ACTIVITY - Ophthalmological; Cytostatic; Antirheumatic;
 Antiarthritic, Antiangiogenic.

MECHANISM OF ACTION - None given in the source material.

USE - (A) is used for treatment/prevention of a disease associated
 with aberrant vascularization (preferably wet type macular degeneration,
 rheumatoid arthritis or cancer) in an animal (preferably a human) that has
 or is at risk for developing the disease (claimed).

ADVANTAGE - (I) displays increased stability and shelf life, without
 significant loss of solubility or therapeutic efficacy. This allows the
 drug to be handled pharmaceutically in bulk without exquisite attention to
 air exclusion. The stability of (I) was studied under conditions that
 exacerbate instability (i.e. by leaving the drug in open Petri dishes at
 room temperature) using a tetrathiomolybdate preparation as control. The
 half life of tetrapropylammonium tetrathiomolybdate
 under these conditions was determined to be about 180 days whereas it was
 about 40 days for the control.

Dwg.0/5